**Table S3. Clinico-pathological Characteristics of Patients.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **MA (n=11)** | **nMA (n=8)** | **P-value** |
| **Gender** |  |  |  |
| Female  | 6 | 2 | 0.352 |
| Male  | 5 | 6 |  |
| **Age (years)a** | 67.8 (63-72.5) | 54.5 (49.75-58.75) | 0.001\* |
| **BMIa** | 25 (22.4-26.05) | 23.7 (21.72-24.2) | 0.432 |
| **Synchronous adenoma** |  |  |  |
| Yes | 7 | 3 | 0.370 |
| No | 4 | 5 |  |
| **Bowel****obstructiond** |  |  |  |
| Yes | 0 | 1 | 0.421 |
| No | 11 | 7 |  |
| **Hematochezia** |  |  |  |
| Yes | 7 | 6 | 1 |
| No | 4 | 2 |  |
| **Tumor sizeac** | 4.3 (3.75-5.75) | 4 (3.35-5) | 0.296 |
| **Tumor locationb** |  |  |  |
| Left hemi-colon | 5 | 0 | 0.158 |
| Right hemi-colon | 1 | 3 |  |
| Rectum | 5 | 5 |  |
| **CEAa** | 5.89 (3.465-12.185) | 7.38 (4.1-21.14) | 0.409 |
| **CA 19-9a** | 9.8 (7.125-17.56) | 14.92 (10.435-85.173) | 0.322 |
| **Adjuvant therapy** |  |  |  |
| Yes | 6 | 6 | 0.633 |
| No | 5 | 2 |  |
| **TNM-Stage** |  |  |  |
| I | 1 | 0 | 0.421 |
| IIA | 6 | 3 |  |
| IIIA | 0 | 0 |  |
| IIIB | 4 | 3 |  |
| IIIC | 0 | 2 |  |

\*P<0.05, different from controls by Wilcoxon rank-sum test or Chi-squared test for continuous or categorical variables, respectively.

a Data shown as median (1st and 3rd quartile).

bTumor location: splenic flexure, descending, sigmoid, rectosigmoid were classified as left hemi-colon; ileocecal, ascending, hepatic flexure, transverse were classified as right hemi-colon.

cTumor size definition: maximum diameter.

dBowel obstruction was defined when coloscopy cannot pass through the tumor obstruction.

CEA: carcinoembryonic antigen.

CA19-9: carbohydrate antigen 19-9.